Meta AnalysisID 7360
丁苯酞联合阿加曲班治疗缺血性卒中的有效性和安全性：系统评价与Meta分析
CRD42023434676
Although many countries and regions have formed a relatively standardized diagnosis and treatment plan for ischemic stroke, poor prognosis is a unresolved problem . The main factors include the development of atheroscler
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 7360
- Evidence Id
- 15918
- Core Evidence Id
- 15918
- Source Meta Analysis Id
- 7347
- Herb2 Meta Analysis Id
- HBMA007347
- Crd Id
- CRD42023434676
- Title
- A systematic review and meta-analysis of the effectiveness and safety of butylphthalide in combination with argatroban in the treatment of ischemic stroke
- Review Question
- Although many countries and regions have formed a relatively standardized diagnosis and treatment plan for ischemic stroke, poor prognosis is a unresolved problem . The main factors include the development of atherosclerosis plaque, which activate the blood coagulation pathway, release of inflammatory factors, and reperfusion injury caused by blood reperfusion. Butylphthalide is a class I innovative drug in China, and its chemical structure is racemic n-butylphthalide. Animal and clinical trials have confirmed that butylphthalide can significantly alleviate the degree of central nervous system injury and reduce reperfusion injury . Agatroban is a direct thrombin inhibitor with small molecular weight, which can penetrate the Blood–brain barrier and inhibit the thrombin free from the lesion site and combined with the blood clot, thus improving the blood supply in the ischemic region . Whether the combination of the two drugs can further improve the prognosis of ischemic stroke patients and provide a better treatment plan for clinical.
- Study Type Included
- Randomized controlled trials
- Condition Being Studied
- Ischemic stroke is the most common type of cerebrovascular disease, accounting for 81.9% of all stroke hospitalizations, and is characterized by high morbidity, high disability, high mortality, and high recurrence rates, the Global Burden of Disease Study (GBD; http://ghdx.healthdata.org/) data show that the incidence of ischemic stroke in China increased from 117/100, 000 in 2005 to 145/100, 000 in 2019.
- Participant
- patients who diagnosised with ischaemic stroke;
- Animal
- Human Disease Modelled
- Intervention
- Butylphthalide combined with argatroban injection
- Comparator Control
- Butylphthalide alone; argatroban injectiona lone
- Main Outcome
- (1)Improvement in neurological function and ability to perform daily living; (2) serum inflammatory factor levels; (3) adverse reactions.
- Outcome Measure
- Additional Outcome
- (1) vascular endothelial function indicators; (2) coagulation index; (3) cerebral blood flow indicators; (4) efficient;
- Study Method
- Intervention, Systematic review
- Keyword
- 3-n-butylphthalide; Animals; Antithrombins; Atherosclerosis; Blood-Brain Barrier; Humans; Ischemic Stroke; Prognosis; Reperfusion; Thrombin; argatroban
- Contact
- zhen yang [email protected]
- Organisational Affiliation
- The Second Hospital of Hebei Medical University
- Funding Source
- none Grant number(s) State the funder, grant or award number and the date of award none
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-06-13
- Registration Date
- 2023-06-23
- Anticipated Start Date
- 2023-06-02
- Anticipated Completion Date
- 2023-09-07
- Title Cn
- 丁苯酞联合阿加曲班治疗缺血性卒中的有效性和安全性：系统评价与Meta分析
- Title En
- A systematic review and meta-analysis of the effectiveness and safety of butylphthalide in combination with argatroban in the treatment of ischemic stroke
- Bilingual Status
- complete